Breast Cancer — Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer
Citation(s)
Phase I/II Trial of ZD1839 (Iressa®), Trastuzumab (Herceptin®), and Docetaxel (Taxotere®) in Patients With erbB-2 (HER-2) Overexpressing, Stage IV Breast Carcinoma